#### Mind the gap Effect of COVID-19 on UK botulinum toxin (BtX) services

Dr Peter Moore

The Walton Centre NHS Foundation Trust

Liverpool, UK

#### Disclosures

Research funding, travel grants, consultancy and speaker payments from Allergan, Ipsen, Merz

#### Current state

- Many BtX clinics have closed to
  - Reduce risk of virus transmission
  - Free up resources to treat COVID-19
- A few still running
  - Depend on local hospital policies
  - Negotiated with individual clinician Leads
  - Mostly limited and / or selected throughput
  - Various conditions imposed around safety and availability of facilities

#### Consequences

- Large and increasing gap in treatment cycles
  - Big impact on
    - patients with short effective cycles
    - patients with critical benefits pain, function, ADLs, carers, work, safety
  - Reverting to alternative treatments
    - Less effective, AEs
  - Anxiety about re-starting BtX clinics
    - Timing and priorities uncertain

# **BNN** Guidelines

- Aim to develop discussion rather than dictate policy
- Identify issues for each service to consider
- Recognise each service has unique constraints and options
- Sent to members rather than published on website

#### Practical issues

- Full or phased return of clinics
- Staff and resource availability
- Strategy for call-up and prioritisation
- Buy-in from patients

# **Clinic Appointment Strategies**

- Restart regular 3 month cycle in booked sequence / from longest interval
- Prioritise patients by severity, risk and disability
- Additional clinics to clear the backlog?
  - but avoid an ongoing 'bulge'?
- How many can you process?

# Efficiency and safety

• Avoid attendance if

- potentially infected, or shielding

- Preparing patients for first visit back
  - Timing of transport to minimise queues
  - Waiting area and treatment room set-up
  - Information to bring
  - Restrictions during clinical interactions

#### **Clinic Room Considerations**

- Social distancing in clinic and waiting room
- PPE (refer to local guidelines)
  - Patient and injector
  - Depends on procedure
- Palpation / injection from behind the patient where possible for CD
- Avoid speaking during procedure

### BtX and COVID-19 interactions

- No known effect of BtX on COVID-19
- ?COVID-19 affects BtX Rx
  - Myalgia (CK), neuropathy, post-viral immune
  - Trauma to local tissues (eg tracheostomy)
  - Drug interactions
  - Susceptibility to anti-toxin antibodies

# Unique natural experiment

- Nature and effect of restart strategies
   Optimum 2<sup>nd</sup> lockdown/unlock policies
- Effect of gap in treatment
  - Patients quality of life
    - Could support improved service provision
    - More susceptible sub-groups
  - Quality of BtX response

#### BtX and underlying disease

– Is effect of BtX different after a gap?


- ?irretrievable reduction in benefit
- ?usual response 1<sup>st</sup> restart cycle, or need several
- Progression of the underlying disease
  - ? Differential effect in eg dystonia / migraine
  - Does severity or apparent pattern dystonia change?

#### Service Evaluation /Audit / Research?

- Unlock timescale and pace uncertain
  - Longer gap more informative
  - Complex prospective studies slow to initiate
  - Red tape
- Restarting clinics very busy
  - Can we use routinely collected information?
  - Minimise in-clinic burden
- Single-centre vs multicentre
  - Numbers, controls

# Mind the Gap

- Service Evaluation
- Livechart to collect process and outcome data
  - In use in some centres already
  - PROM single sheet / cycle, completed by patient
  - Scan and email to collection point
- Collect for 4 cycles
  - Pre-Lockdown prospective / retrospective



#### Section 3.

Continued overleaf

a. How soon did you feel some effect?	days/weeks
b. How long before it was working reasonably well?	days/weeks
c. How long did this response last?	days/weeks
d. How long ago did it start to wear off?	days/weeks
e. For how long has it not been working well enough?	days/weeks
f. How long since it wore off completely?	days/weeks

Section 4. Did you experience any side effects? Please describe these side effects in the boxes below.

Side effects	Start - days/weeks	End – days/weeks	How long did it last?	Severity - Mild/Moderate/Severe
1				
2				
3				
4				

Section 5. While it was working what was the effect of your injection?


Major Moderate Minor	No effect	Minor	Moderate	Major
deterioration deterioration		benefit	benefit	benefit

Section 6. How did it compare with your previous injection?

Much worse Worse Slightly wo	e Same Slightly better	er Better Much better	r
------------------------------	------------------------	-----------------------	---

Devised by Dr AP Moore, The Walton Centre NHS Foundation Trust. Presented with compliments by Ipsen Ltd

#### Classic response



# Not used Livechart?

- For any condition treated with BtX
  - Simplifies clinic, avoids disease-specific scales
  - Same chart for multiple conditions
- Clear record treatment and effect on one page
- Takes 3-4 minutes to explain first time
  Training video and instructions online
- Improves patient understanding and engagement
- Speeds up FU visits

# Data analysis

- Condition treated / differential effect
- Dose and distribution
- Response
  - Likert scores
  - VAS analysis
  - Adverse effects
- Could be compared to any disease-specific scale data also collected routinely

## Interested in principle?

- Please indicate using screen button
- Will hold a further webinar: time tbc
- Any thoughts / ideas welcome
- Propose a collaboration clinical centres and patient groups

mindthegap@thewaltoncentre.nhs.uk

#### Mind the gap Effect of COVID-19 on UK botulinum toxin (BtX) services

Dr Peter Moore

The Walton Centre NHS Foundation Trust

Liverpool, UK